secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001104659-25-121180
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel stockholders approve reverse stock split authorization and elect directors
--------------------------------------------------------------------------------

- All five proposals passed at Dec 12 annual meeting; 44.68% of shares voted.
- Directors June Bray, Sandeep Laumas, David Mack elected as Class I directors.
- Ernst & Young ratified as independent auditor for FY2025.
- Advisory say-on-pay approved with ~78% of votes cast (excl. broker non-votes).
- Stockholders authorized reverse stock split of 1:2 to 1:20 to regain Nasdaq bid price compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925121180/0001104659-25-121180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925121180/tm2533533d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-121180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer